These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serial quantitative coronary angiography and coronary events. Mack WJ; Xiang M; Selzer RH; Hodis HN Am Heart J; 2000 Jun; 139(6):993-9. PubMed ID: 10827379 [TBL] [Abstract][Full Text] [Related]
3. Correlations between measures of atherosclerosis change using carotid ultrasonography and coronary angiography. Mack WJ; LaBree L; Liu C; Selzer RH; Hodis HN Atherosclerosis; 2000 Jun; 150(2):371-9. PubMed ID: 10856529 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of colestipol/niacin therapy with computer-derived coronary end point measures. A comparison of different measures of treatment effect. Blankenhorn DH; Selzer RH; Mack WJ; Crawford DW; Pogoda J; Lee PL; Shircore AM; Azen SP Circulation; 1992 Dec; 86(6):1701-9. PubMed ID: 1451241 [TBL] [Abstract][Full Text] [Related]
5. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. Brown G; Albers JJ; Fisher LD; Schaefer SM; Lin JT; Kaplan C; Zhao XQ; Bisson BD; Fitzpatrick VF; Dodge HT N Engl J Med; 1990 Nov; 323(19):1289-98. PubMed ID: 2215615 [TBL] [Abstract][Full Text] [Related]
6. Evidence for a new pathophysiological mechanism for coronary artery disease regression: hepatic lipase-mediated changes in LDL density. Zambon A; Hokanson JE; Brown BG; Brunzell JD Circulation; 1999 Apr; 99(15):1959-64. PubMed ID: 10208998 [TBL] [Abstract][Full Text] [Related]
7. Serial coronary angiographic evidence that antioxidant vitamin intake reduces progression of coronary artery atherosclerosis. Hodis HN; Mack WJ; LaBree L; Cashin-Hemphill L; Sevanian A; Johnson R; Azen SP JAMA; 1995 Jun; 273(23):1849-54. PubMed ID: 7776501 [TBL] [Abstract][Full Text] [Related]
8. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. Blankenhorn DH; Nessim SA; Johnson RL; Sanmarco ME; Azen SP; Cashin-Hemphill L JAMA; 1987 Jun; 257(23):3233-40. PubMed ID: 3295315 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of two lipid-lowering treatments on quantitative coronary angiographic endpoints. Mack WJ; Xiang M; Shircore AM; Selzer RH; Hodis HN; Azen SP Cardiovasc Drugs Ther; 2000 Aug; 14(4):411-8. PubMed ID: 10999648 [TBL] [Abstract][Full Text] [Related]
10. Comparison of computer- and human-derived coronary angiographic end-point measures for controlled therapy trials. Mack WJ; Selzer RH; Pogoda JM; Lee PL; Shircore AM; Azen SP; Blankenhorn DH Arterioscler Thromb; 1992 Mar; 12(3):348-56. PubMed ID: 1547194 [TBL] [Abstract][Full Text] [Related]
12. Reversibility of atherosclerosis--evolving perspectives from two arterial imaging clinical trials: the cholesterol lowering atherosclerosis regression study and the monitored atherosclerosis regression study. Hodis HN J Cardiovasc Pharmacol; 1995; 25 Suppl 4():S25-31. PubMed ID: 8907211 [TBL] [Abstract][Full Text] [Related]
13. Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Frick MH; Syvänne M; Nieminen MS; Kauma H; Majahalme S; Virtanen V; Kesäniemi YA; Pasternack A; Taskinen MR Circulation; 1997 Oct; 96(7):2137-43. PubMed ID: 9337181 [TBL] [Abstract][Full Text] [Related]
14. Effects of intensive lipid-lowering therapy on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Zhao XQ; Brown BG; Hillger L; Sacco D; Bisson B; Fisher L; Albers JJ Circulation; 1993 Dec; 88(6):2744-53. PubMed ID: 8252687 [TBL] [Abstract][Full Text] [Related]
15. One-year reduction and longitudinal analysis of carotid intima-media thickness associated with colestipol/niacin therapy. Mack WJ; Selzer RH; Hodis HN; Erickson JK; Liu CR; Liu CH; Crawford DW; Blankenhorn DH Stroke; 1993 Dec; 24(12):1779-83. PubMed ID: 8248954 [TBL] [Abstract][Full Text] [Related]
16. Secondary preventive potential of lipid-lowering drugs. The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECAIT). de Faire U; Ericsson CG; Grip L; Nilsson J; Svane B; Hamsten A Eur Heart J; 1996 Dec; 17 Suppl F():37-42. PubMed ID: 8960446 [TBL] [Abstract][Full Text] [Related]
17. Prediction of angiographic change in native human coronary arteries and aortocoronary bypass grafts. Lipid and nonlipid factors. Blankenhorn DH; Alaupovic P; Wickham E; Chin HP; Azen SP Circulation; 1990 Feb; 81(2):470-6. PubMed ID: 2404631 [TBL] [Abstract][Full Text] [Related]